New therapies are currently being developed in the field of skin cancer. In particular, advances in melanoma now represent the frontline of cancer immunotherapy, as immunological findings in the disease have led to the development of highly effective immune-checkpoint inhibitors. However, these immune-checkpoint inhibitors are only effective in a subset of patients, and may not work in other skin cancer types, thus highlighting the need for further innovation in the field of skin cancer treatment.
The purpose of this Research Topic is therefore to provide an up-to-date overview of immune processes and new therapies for melanoma and other skin cancers in order to further stimulate the development of new and even more successful treatments.
We are welcoming experts in the fields of immunology and dermatology to submit review articles summarizing the latest insights into immune responses and/or therapies (immunological and non-immunological) of skin malignancies, including: melanoma, basal cell carcinoma, squamous cell carcinoma, extramammary Paget’s disease, Merkel cell carcinoma, cutaneous angiosarcoma, and cutaneous T-Cell Lymphoma.
New therapies are currently being developed in the field of skin cancer. In particular, advances in melanoma now represent the frontline of cancer immunotherapy, as immunological findings in the disease have led to the development of highly effective immune-checkpoint inhibitors. However, these immune-checkpoint inhibitors are only effective in a subset of patients, and may not work in other skin cancer types, thus highlighting the need for further innovation in the field of skin cancer treatment.
The purpose of this Research Topic is therefore to provide an up-to-date overview of immune processes and new therapies for melanoma and other skin cancers in order to further stimulate the development of new and even more successful treatments.
We are welcoming experts in the fields of immunology and dermatology to submit review articles summarizing the latest insights into immune responses and/or therapies (immunological and non-immunological) of skin malignancies, including: melanoma, basal cell carcinoma, squamous cell carcinoma, extramammary Paget’s disease, Merkel cell carcinoma, cutaneous angiosarcoma, and cutaneous T-Cell Lymphoma.
